OLMA
Olema Pharmaceuticals, Inc.
Latest Form 4:Sale$145KbyHarmon Cyrus (Director) · filed Jul 27, 2026
Olema Pharmaceuticals, Inc. (OLMA) has 7 SEC Form 4 filings (19 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: Jul 27, 2026.
The most active filer is Director Harmon Cyrus with 4 filings. Insiders have net sold $1.2M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Sean Bohen
- Employees:137
- HQ:San Francisco, CA, US
- IPO:2020-11-19
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$7.7M
reported sales (SEC code S)
Unique Insiders
4
in the rolling window
Market Cap
$911.9M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Harmon CyrusFirst in 6 months | Director | Sale | 12,500 | $145K | Jul 27 | SEC ↗ |
Harmon CyrusFirst in 6 months | Director | Sale | 12,500 | $146K | Jul 27 | SEC ↗ |
Mitchell ShawnteFirst filing | CHIEF LEGAL OFFICER | Sale | 15,000 | $345K | Mar 5 | SEC ↗ |
Mitchell ShawnteFirst filing | CHIEF LEGAL OFFICER | Sale | 25,000 | $606K | Mar 5 | SEC ↗ |
| Director | Sale | 10,000 | $269K | Jan 21 | SEC ↗ | |
Harmon CyrusFirst filing | Director | Sale | 3,489 | $102K | Jan 16 | SEC ↗ |
Kovacs Shane William CharlesFirst filing | CH. OPERATING & FINANCIAL OFF. | Sale | 3,822 | $107K | Jan 15 | SEC ↗ |
Kovacs Shane William CharlesFirst filing | CH. OPERATING & FINANCIAL OFF. | Sale | 100,000 | $2.9M | Jan 15 | SEC ↗ |
Myles David C.First filing | CH. DISCOV. & NON-CLIN DEV OFF | Sale | 10,000 | $283K | Jan 14 | SEC ↗ |
Myles David C.First filing | CH. DISCOV. & NON-CLIN DEV OFF | Sale | 50,000 | $1.4M | Jan 14 | SEC ↗ |
Myles David C.First filing | CH. DISCOV. & NON-CLIN DEV OFF | Sale | 50,000 | $1.4M | Jan 14 | SEC ↗ |
Related companies
Olema Pharmaceuticals, Inc. is in the Healthcare sector.